Home » Newsletters » BioWorld Science

BioWorld Science

March 26, 1997

View Archived Issues

Sankyo prepares ACAT inhibitors

Sumitomo reveals antipsychotic agents with reduced side effects

Taiho discloses antiangiogenic agents

Hypoglycemic/hypolipidemic agents from Kyorin

Novel antibiotic isolated by Kitasato Institute and Chinese Academy of Medical Science

Kitasato Institute discovers inhibitor of IL-6 activity

Cysteine protease inhibitors described by Senju

Novel recombinant protein for bone diseases from Hoechst

Fujisawa obtains natural antifungal agent

PGD2 antagonists claimed by Shionogi

Research on cardiovascular drugs reported at the meeting of the Japanese Circulation Society

Antidepressant effects of NKH-477

ME-3167 heading for NDA submission

Meiji Seika antibiotic scheduled for launch in Europe in 1998

Novel antipsychotic agent reported by Asahi Chemical

DepoTech's new formulation of morphine sulfate enters phase I

Cor Therapeutics receives nonapprovable letter for Integrilin NDA

Cubist Pharmaceuticals and Genzyme enter compound library screening collaboration

Aphton issued U.S. patents covering Gastrimmune

Synsorb Cd enters phase II

Cangene signs distribution agreement for WinRho SDF

Biogen licenses Hirulog

Luvox cleared for OCD in children and adolescents

Axcan receives approvable letter for URSO from FDA

U.S. patent covers Connetics TCR vaccine technology

Biological role of CD39 uncovered by Immunex and collaborators

Subcutaneous IL-2 boosts CD4 cell counts in HIV-infected patients

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...